周围保护肺癌免受向治疗,通过多个分子媒介的联合作用来保护肺癌
bioRxiv : the preprint server for biology
|May 7, 2024
概括
瘤流层保护癌细胞免受ALK抑制剂的影响,例如在非小细胞肺癌 (NSCLC) 中的alectinib. 针对多个耐药机制或附带敏感性是克服治疗耐药性的关键.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 向疗法,如对ALK+非小细胞肺癌 (NSCLC) 的阿纳普拉斯性淋巴瘤激酶 (ALK) 抑制剂,诱导反应,但没有治愈作用.
- 瘤细胞可以持续存在并发展出抵抗力,受到内在因素和瘤微环境的影响.
- 瘤侧膜在介导治疗耐药性的作用in vivo还不清楚.
研究的目的:
- 对ALK+NSCLC中介性抗性对治疗反应的贡献进行调查.
- 为了评估针对ALK抑制剂alectinib的向 stromal抵抗机制的疗效.
主要方法:
- 使用ALK抑制剂alectinib治疗ALK+NSCLC的异种移植模型.
- 在治疗和复发期间评估瘤侧膜对癌细胞的保护作用.
- 研究了多种阻力机制,包括生长因子和细胞外矩阵组件.
主要成果:
- 靠近侧膜的瘤细胞显示对alectinib的细胞静止作用的部分保护,在缓解和复发中观察到.
- 斯特罗玛介导的耐药性涉及多种机制,包括生长因子和细胞外基质.
- 抑制个体抵抗机制不足以克服树皮保护.
结论:
- 瘤筋膜显著促进ALK+NSCLC治疗持久性和耐药性.
- 准树皮抵抗需要解决多种机制或利用附带敏感性.
- 结合方法,如抗体-药物结合剂与旁观者效应,可以克服斯特罗玛介导的抗性并限制治疗逃逸.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Stem Cell Niche
5.1K
The stem cell niche is the dynamic microenvironment where stem cells reside. Inside these niches, the cells may remain undifferentiated, undergo high self-renewal, or become lineage-specific progenitors. Stem cells coexist with other niche cells, such as stromal cells. They also interact closely with the ECM. Cell-cell and cell-matrix communication occur via adhesion molecules or soluble factors that signal the stem cells and determine their fate. Stromal cells also provide survival signals to...
5.1K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


